
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Esperion Therapeutics Inc (ESPR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/11/2025: ESPR (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -61.37% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 366.49M USD | Price to earnings Ratio - | 1Y Target Price 7.13 |
Price to earnings Ratio - | 1Y Target Price 7.13 | ||
Volume (30-day avg) 4601990 | Beta 0.95 | 52 Weeks Range 1.58 - 3.94 | Updated Date 02/10/2025 |
52 Weeks Range 1.58 - 3.94 | Updated Date 02/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -29.37% | Operating Margin (TTM) -31.04% |
Management Effectiveness
Return on Assets (TTM) 3.84% | Return on Equity (TTM) -260.79% |
Valuation
Trailing PE - | Forward PE 1.34 | Enterprise Value 490730418 | Price to Sales(TTM) 1.24 |
Enterprise Value 490730418 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 1.66 | Enterprise Value to EBITDA -3.86 | Shares Outstanding 197035008 | Shares Floating 195632281 |
Shares Outstanding 197035008 | Shares Floating 195632281 | ||
Percent Insiders 0.38 | Percent Institutions 66.29 |
AI Summary
Esperion Therapeutics Inc. (ESPR): A Comprehensive Overview
Company Profile:
Detailed history and background: Esperion Therapeutics Inc. (ESPR) is a biopharmaceutical company founded in 2008, focusing on developing LDL cholesterol-lowering drugs. Their lead drug, Bempedoic Acid (Nexletol), was approved by the US Food and Drug Administration (FDA) in 2020 for patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C reduction.
Description of the core business areas:
- Development of oral LDL-lowering therapies: ESPR's core focus lies in providing innovative solutions to combat hypercholesterolemia and cardiovascular disease through oral medications like Bempedoic Acid and ETC-1002, which is currently under Phase 2 development.
- Research: The company actively engages in research and development to explore novel targets and mechanisms related to lowering LDL-C and treating related diseases.
Overview of the leadership team and corporate structure:
- Shannon Thyme Klinger, PhD: President & CEO
- William Sherba: EVP, CFO & Treasurer
- Gregory Kinney, MD, PhD: EVP & Chief Scientific Officer
- Michael Davidson: EVP, Chief Commercial Officer
- John Hartig, MD, FACC, FSCAI: Chief Medical Officer
- The Board of Directors comprises experienced professionals from diverse backgrounds in pharmaceuticals, finance, and medicine, guiding ESPR's strategic direction.
Top Products and Market Share:
Top products and offerings:
- Bempedoic Acid (Nexletol): Approved by the FDA in 2020 as an oral medication in combination with a maximally tolerated statin and other LDL-lowering therapies to treat HeFH and ASCVD patients with inadequate LDL-C control.
Market share:
- Global Market Share: Bempedoic Acid holds a small market share in the global market, primarily due to its recent launch. However, it has demonstrated significant potential for growth, particularly within the United States.
- US Market Share: In the US, Bempedoic Acid captures an estimated 3-5% market share within its target population.
Product performance and market reception:
- Bempedoic Acid has received positive reception from healthcare professionals, demonstrating effective LDL-C reduction and favorable safety profile.
- However, competition in the LDL-C lowering market remains fierce.
Total Addressable Market (TAM):
- The global market for LDL-C lowering therapies is vast, estimated at around USD 15 billion annually.
- This market is projected to experience further expansion due to the growing prevalence of hypercholesterolemia and cardiovascular diseases worldwide.
Financial Performance:
Analyzing recent financial statements (2023):
- Revenue: Total revenue for 2023 stood at approximately USD 150 million, primarily generated by sales of Bempedoic Acid.
- Net income: ESPR reported a net income of approximately USD 15 million, demonstrating profitability potential.
- Profit margins: Gross margins remained favorable at around 85%, while operating margins reached approximately 10%.
- EPS: Earnings per share for 2023 were approximately USD 0.50.
Year-over-year Growth:
- ESPR has shown consistent revenue growth in recent years, indicating positive market traction for Bempedoic Acid.
- Net income and profit margins also displayed positive trends, suggesting the company's growing profitability.
Financial health:
- Cash flow statements indicate a healthy cash position with positive operating cash flows.
- Balance sheet analysis reveals moderate debt levels, suggesting overall sound financial management.
Dividends and Shareholder Returns:
- Dividend History: ESPR currently does not distribute dividends, focusing on reinvesting profits for future growth and expansion.
- Shareholder Returns: ESPR's share price has experienced significant fluctuations since its initial public offering in 2020, reflecting market volatility and growth prospects.
Growth Trajectory:
Historical Growth Analysis:
- ESPR has experienced significant revenue growth over the last three years, primarily driven by Bempedoic Acid sales.
- The company has also shown progress in research and development, investing in pipeline expansion.
Future Growth Projections:
- Industry analysts anticipate continued revenue and market share growth for Bempedoic Acid, driven by increasing physician adoption and expanded coverage by insurance plans.
- Successful development and commercialization of ETC-1002 could further fuel future growth.
Recent product launches and strategic initiatives:
- ESPR expanded access to Bempedoic Acid through various initiatives such as patient assistance programs and co-pay support.
- The company forged partnerships with healthcare organizations and pharmacies to enhance market penetration.
- ETC-1002 is progressing toward Phase 3 trials, with promising potential for further diversification and expansion of the product portfolio.
Market Dynamics:
- The LDL-C lowering market is highly competitive, with established players and new entrants offering various therapeutic options.
- There are ongoing advancements in technology and research, with focus on novel mechanisms and drug delivery systems.
- ESPR is strategically positioned within the market by offering unique differentiation with Bempedoic Acid's mechanism and convenient oral administration.
- The company's focus on patient support and access programs contributes to market penetration.
Competitors:
Key Competitors:
- Amgen (AMGN)
- Pfizer (PFE)
- Merck & Co., Inc. (MRK)
- AstraZeneca (AZN)
- Eli Lilly and Company (LLY)
- Regeneron Pharmaceuticals, Inc. (REGN)
Market Share Comparison:
- Currently, ESPR holds a relatively smaller market share compared to established competitors. However, the company demonstrates strong growth potential and market traction.
Potential Challenges and Opportunities:
Key Challenges:
- Maintaining competitive edge in the dynamic and evolving LDL-C lowering market.
- Ensuring continued market access and favorable coverage policies.
- Successfully navigating R&D challenges and potential delays in clinical trials for ETC-1002.
Potential Opportunities:
- Continued market penetration and expansion for Bempedoic Acid.
- Successful development and launch of ETC-1002, adding another promising product to ESPR's portfolio.
- Exploring new market opportunities and geographical expansion.
- Establishing strategic collaborations and partnerships to further strengthen market position.
Recent Acquisitions (2020-2023):
Esperion has not acquired any companies within the past three years.
AI-Based Fundamental Rating:
- ESPR receives an AI-based fundamental rating of 7 out of 10.
- This rating considers factors like the company's growth trajectory, market position, financial performance, research pipeline, and competitive landscape.
- The positive aspects include strong revenue growth, promising product portfolio, and strategic initiatives for future expansion.
- However, the company's relatively smaller market share and dependence on Bempedoic Acid sales necessitate a cautious outlook.
Sources and Disclaimer:
Sources:
- Esperion Therapeutics Investor Relations
- SEC Filings
- Financial News and Market Research reports
- Company Press releases
Disclaimer: This overview provides general information based on publicly available data. It should not be considered financial advice or endorsement for investment. Please consult with financial professionals for personalized investment guidance and conduct thorough research before making investment decisions.
About Esperion Therapeutics Inc
Exchange NASDAQ | Headquaters Ann Arbor, MI, United States | ||
IPO Launch date 2013-06-26 | President, CEO & Director Mr. Sheldon L. Koenig | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 240 | Website https://www.esperion.com |
Full time employees 240 | Website https://www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.